Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$271000.0.

  • Harvard Bioscience's Change in Accured Expenses fell 183571.43% to -$271000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1000.0, marking a year-over-year increase of 10019.69%. This contributed to the annual value of -$1.8 million for FY2024, which is 24130.02% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Change in Accured Expenses is -$271000.0, which was down 183571.43% from $302000.0 recorded in Q2 2025.
  • Harvard Bioscience's 5-year Change in Accured Expenses high stood at $2.7 million for Q1 2022, and its period low was -$4.5 million during Q4 2021.
  • In the last 5 years, Harvard Bioscience's Change in Accured Expenses had a median value of -$225000.0 in 2023 and averaged -$250473.7.
  • Per our database at Business Quant, Harvard Bioscience's Change in Accured Expenses soared by 66016.48% in 2024 and then tumbled by 183571.43% in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's Change in Accured Expenses stood at -$4.5 million in 2021, then soared by 121.99% to $980000.0 in 2022, then tumbled by 122.96% to -$225000.0 in 2023, then tumbled by 567.56% to -$1.5 million in 2024, then skyrocketed by 81.96% to -$271000.0 in 2025.
  • Its Change in Accured Expenses was -$271000.0 in Q3 2025, compared to $302000.0 in Q2 2025 and $1.5 million in Q1 2025.